Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.
Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X, Koeppen H, Assaf ZJ, Nabet BY, Waddell A, Yuen K, Maund S, Sokol E, Giltnane JM, Schedlbauer A, Fuentes E, Cowan JD, Kadel EE 3rd, Degaonkar V, Andreev-Drakhlin A, Williams P, Carter C, Gupta S, Steinberg E, Loriot Y, Bellmunt J, Grivas P, Rosenberg J, van der Heijden MS, Galsky MD, Powles T, Mariathasan S, Banchereau R.
Hamidi H, et al. Among authors: waddell a.
Cancer Cell. 2024 Nov 16:S1535-6108(24)00404-5. doi: 10.1016/j.ccell.2024.10.016. Online ahead of print.
Cancer Cell. 2024.
PMID: 39577421